Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $13.7 million.

  • BioLineRx's Total Current Liabilities fell 4524.08% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 4524.08%. This contributed to the annual value of $15.4 million for FY2024, which is 6399.12% down from last year.
  • As of Q3 2025, BioLineRx's Total Current Liabilities stood at $13.7 million, which was down 4524.08% from $15.5 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Total Current Liabilities registered a high of $42.8 million during Q4 2023, and its lowest value of $12.0 million during Q1 2023.
  • Over the past 3 years, BioLineRx's median Total Current Liabilities value was $15.4 million (recorded in 2024), while the average stood at $20.7 million.
  • The largest annual percentage gain for BioLineRx's Total Current Liabilities in the last 5 years was 16055.14% (2024), contrasted with its biggest fall of 6399.12% (2024).
  • Over the past 3 years, BioLineRx's Total Current Liabilities (Quarter) stood at $42.8 million in 2023, then plummeted by 63.99% to $15.4 million in 2024, then decreased by 11.27% to $13.7 million in 2025.
  • Its Total Current Liabilities was $13.7 million in Q3 2025, compared to $15.5 million in Q2 2025 and $14.0 million in Q1 2025.